Pharmaceutical

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

Next Article

BNT-325 by Duality Biologics (Shanghai) for Metastatic Ovarian Cancer: Likelihoo...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FTC countersues HCA, Louisiana hospital system to stop acquisitions

STAT+: FTC countersues HCA, Louisiana hospital system t...

Apr 21, 2023

STAT+: Learning to treat long COVID could help those struggling with chronic fatigue syndrome, too

STAT+: Learning to treat long COVID could help those st...

May 23, 2023

Lawmakers call on FDA to issue stricter bone graft guidance

Lawmakers call on FDA to issue stricter bone graft guid...

Aug 31, 2023